United Therapeutics Corporation (UTHR) Stock Analysis
A live, multi-source view of United Therapeutics Corporation (UTHR): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About United Therapeutics Corporation
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products.
Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic · United States · 1,400 employees · unither.com
Key statistics · as of 2026-09-06
As of 2026-09-06, United Therapeutics Corporation (UTHR) had a market capitalization of $20.91B, a trailing P/E of 17.5 (forward 16.2) and a beta of 0.56; the shares traded in a 52-week range of $388.73 – $609.35 (23.6% over the year).
- Market cap
- $20.91B
- Enterprise value
- $18.25B
- Trailing P/E
- 17.5
- Forward P/E
- 16.2
- PEG ratio
- 2.22
- Price / book
- 3.25
- EPS (trailing)
- $27.89
- EPS (forward)
- $30.03
- Payout ratio
- 0.0%
- 52-week range
- $388.73 – $609.35
- 52-week change
- 23.6%
- Beta
- 0.56
- Average volume
- 514,146
- Shares outstanding
- 42.9M
- Short % of float
- 5.75%
- Profit margin
- 41.6%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, United Therapeutics Corporation (UTHR) last closed at $503.86 (the last completed close before that scan).
Technicals at the scan: RSI 45 (neutral territory), price -1.0% versus its 20-day average, 20-day versus 50-day average spread -2.7%, MACD histogram -0.43.
Sentiment inputs: 100% of recent Finnhub-scored headlines read bullish; StockTwits 65% bullish; analyst consensus score 75/100.
Next scheduled company event: in 47 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of UTHR; corporate insiders filed 0 buys and 454 sells (2 distinct filers, latest disclosure 2026-09-10). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Martine A. Rothblatt (0B/426S), Paul A. Mahon (0B/28S). Who is trading what
RapidTradeView pick record
UTHR has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls United Therapeutics Corporation (UTHR) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell UTHR.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.